EGFR activation sensitizes trigeminal NMDA receptors to promote pain and morphine analgesic tolerance in oral cancer.

Pain associated with oral cancer is debilitating. Opioids are the gold standard for cancer pain management, but tolerance and side effects limit their use. Epidermal growth factor receptor (EGFR) signaling is commonly amplified in oral tumors. Here, we found that EGFR activation contributed to both oral cancer pain and opioid tolerance by sensitizing trigeminal ganglion (TG) cells, the main sensory neurons innervating the face and mouth. EGFR ligands were secreted by oral squamous cell carcinoma (OSCC) cells and by peripheral glial cells cocultured with OSCC cells. In human OSCC and an orthotopic mouse model, EGFR was abundant in tumor-innervating TG nerves. Oral cancer pain and opioid tolerance in the mice were increased by EGFR ligands and reduced by EGFR inhibitors. In mice, the abundance of glutamate-type NMDA receptors (NMDARs) was also increased in both the TG and the brainstem. Upon activation by ligands or OSCC cell supernatant, EGFR phosphorylated the NMDAR subunit GluN2B, which increased electrical currents and sensitized pre- and postsynaptic NMDARs in the brainstem. This sensitization was also seen in the brainstems of mice receiving chronic morphine treatment and was mitigated by EGFR blockade. These findings suggest that EGFR-targeted cancer therapeutics may be repurposed to manage cancer pain and reduce opioid tolerance in patients with OSCC.

• Publication year

  2026

• Venue

  Science Signaling

• Publication date

  2026-01-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1126/scisignal.adt3026PMID 41592151
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Perineural invasion is associated with function-evoked pain and altered extracellular matrix in patients with head and neck squamous cell carcinoma.

  2024cited by this paper
• mGluR5 from primary sensory neurons promotes opioid-induced hyperalgesia and tolerance by interacting with and potentiating synaptic NMDA receptors.

  2023cited by this paper
• Assessing Orofacial Pain Behaviors in Animal Models: A Review

  2023cited by this paper
• NMDA Receptors at Primary Afferent–Excitatory Neuron Synapses Differentially Sustain Chemotherapy- and Nerve Trauma-Induced Chronic Pain

  2023cited by this paper
• A pilot study to improve pain phenotyping in head and neck cancer patients

  2023cited by this paper
• Targeting Peripheral N-Methyl-D-Aspartate Receptor (NMDAR): A Novel Strategy for the Treatment of Migraine

  2023cited by this paper
• Calcitonin Related Polypeptide Alpha Mediates Oral Cancer Pain

  2023cited by this paper
• Activation of the N-methyl-D-aspartate receptor contributes to orofacial neuropathic and inflammatory allodynia by facilitating calcium-calmodulin-dependent protein kinase II phosphorylation in mice.

  2022cited by this paper
• Brief Opioid Exposure Paradoxically Augments Primary Afferent Input to Spinal Excitatory Neurons via α2δ-1–Dependent Presynaptic NMDA Receptors

  2022cited by this paper
• The impact of tumor immunogenicity on cancer pain phenotype using syngeneic oral cancer mouse models

  2022cited by this paper
• Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer

  2022cited by this paper
• Association Between EGFR and ALK Mutation Status on Patient-Reported Symptoms After Palliative Radiation for Bone Pain in NSCLC

  2022cited by this paper
• Advances in Head and Neck Cancer Pain

  2022cited by this paper
• Addressing opioid tolerance and opioid‐induced hypersensitivity: Recent developments and future therapeutic strategies

  2021cited by this paper
• Morphine promotes microglial activation by upregulating the EGFR/ERK signaling pathway

  2021cited by this paper
• MicroRNA-183 attenuates osteoarthritic pain by inhibiting the TGFα-mediated CCL2/CCR2 signalling axis

  2021cited by this paper
• Protein Kinase C-Mediated Phosphorylation and α2δ-1 Interdependently Regulate NMDA Receptor Trafficking and Activity

  2021cited by this paper
• Activation of the spinal EGFR signaling pathway in a rat model of cancer-induced bone pain with morphine tolerance.

  2021cited by this paper
• EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance

  2021cited by this paper
• A ligand-receptor interactome platform for discovery of pain mechanisms and therapeutic targets

  2021cited by this paper
• EGFR Signaling Causes Morphine Tolerance and Mechanical Sensitization in Rats

  2020cited by this paper
• ADAM17-EGFR signaling contributes to oral cancer pain.

  2020cited by this paper
• ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain.

  2020cited by this paper
• The dichotomous role of epiregulin in pain.

  2020cited by this paper
• Presynaptic NMDA receptors control nociceptive transmission at the spinal cord level in neuropathic pain

  2019cited by this paper
• μ‐Opioid receptors in primary sensory neurons are essential for opioid analgesic effect on acute and inflammatory pain and opioid‐induced hyperalgesia

  2019cited by this paper
• Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer

  2019cited by this paper
• Expanding Role of NMDA Receptor Antagonists in the Management of Pain

  2019cited by this paper
• Epiregulin is released from intervertebral disks and induces spontaneous activity in pain pathways

  2019cited by this paper
• Relief of Neuropathic Pain Through Epidermal Growth Factor Receptor Inhibition: A Randomized Proof-of-Concept Trial.

  2019cited by this paper
• The upregulation of EGFR in the dorsal root ganglion contributes to chronic compression of dorsal root ganglions-induced neuropathic pain in rats

  2019cited by this paper
• Von Frey testing revisited: Provision of an online algorithm for improved accuracy of 50% thresholds

  2019cited by this paper
• Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B‐containing N‐methyl‐d‐aspartate–sensitive glutamate receptor signaling

  2018cited by this paper
• Long-Term Depression Induced by Optogenetically Driven Nociceptive Inputs to Trigeminal Nucleus Caudalis or Headache Triggers

  2018cited by this paper
• Anti‐cancer and analgesic effects of resolvin D2 in oral squamous cell carcinoma

  2018cited by this paper
• The α2δ-1-NMDA Receptor Complex Is Critically Involved in Neuropathic Pain Development and Gabapentin Therapeutic Actions

  2018cited by this paper
• The α2δ-1–NMDA receptor coupling is essential for corticostriatal long-term potentiation and is involved in learning and memory

  2018cited by this paper
• Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Anti–CD44-Based NIR-PIT

  2017cited by this paper
• EGFR-targeted therapies in the post-genomic era

  2017cited by this paper
• Epiregulin and EGFR interactions are involved in pain processing.

  2017cited by this paper
• Tumor necrosis factor alpha secreted from oral squamous cell carcinoma contributes to cancer pain and associated inflammation

  2017cited by this paper
• EGFR signaling upregulates surface expression of the GluN2B-containing NMDA receptor and contributes to long-term potentiation in the hippocampus.

  2015cited by this paper
• Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain.

  2015cited by this paper
• Adenosine triphosphate drives head and neck cancer pain through P2X2/3 heterotrimers

  2014cited by this paper
• IB4(+) and TRPV1(+) sensory neurons mediate pain but not proliferation in a mouse model of squamous cell carcinoma

  2014cited by this paper
• Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).

  2014cited by this paper
• Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain–A case series

  2013cited by this paper
• A new treatment principle for neuropathic pain? Approved oncologic drugs: Epidermal growth factor receptor (EGFR) inhibitors dramatically relieve severe neuropathic pain in a case series

  2013cited by this paper
• Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition

  2013cited by this paper
• Biologic Mechanisms of Oral Cancer Pain and Implications for Clinical Therapy

  2012cited by this paper
• Chronic opioid potentiates presynaptic but impairs postsynaptic N-methyl-D-aspartic acid receptor activity in spinal cords: implications for opioid hyperalgesia and tolerance.

  2012cited by this paper
• Targeting N-methyl-D-aspartate receptors for treatment of neuropathic pain

  2011cited by this paper
• Heparin-binding epidermal growth factor-like growth factor is a potent regulator of invasion activity in oral squamous cell carcinoma

  2011cited by this paper
• Opioid-Induced Long-Term Potentiation in the Spinal Cord Is a Presynaptic Event

  2010cited by this paper
• Generation and Characterization of Conditional Heparin-Binding EGF-Like Growth Factor Knockout Mice

  2009cited by this paper
• Validation of the University of California San Francisco Oral Cancer Pain Questionnaire.

  2007cited by this paper
• Prevalence of pain in patients with cancer: a systematic review of the past 40 years.

  2007cited by this paper
• The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications

  2006cited by this paper
• A Prospective Study of Quality of Life in Head and Neck Cancer Patients. Part I: At Diagnosis

  2001cited by this paper
• Monitoring of opioid therapy in advanced cancer pain patients.

  1997cited by this paper
• Quantitative assessment of tactile allodynia in the rat paw.

  1994cited by this paper
• TGF‐α and EGFR in head and neck cancer

  1993cited by this paper
• TGF-alpha and EGFR in head and neck cancer.

  1993cited by this paper
• Protein kinase C reduces Mg2+ block of NMDA-receptor channels as a mechanism of modulation

  1992cited by this paper

• No citing papers are available for this paper.